Viking Therapeutics (VKTX) Price Target Raised by Citi to $38

Citi has boosted its price target for Viking Therapeutics (VKTX) from $31 to $38, maintaining a Neutral rating. The firm expects growing investor interest as Phase 2 data for VK2735 approaches in 2025. The average target price for VKTX is $89.19, implying an upside of 167.03% from the current price. Viking Therapeutics reported Q2 2025 financial results, with a net loss of $65.6 million or $0.58 per share. The company maintains a strong financial position with over $800 million in cash.

Title: Viking Therapeutics (VKTX) Sees Positive Analyst Ratings and Financial Position Amid Upcoming Clinical Trials

Viking Therapeutics (VKTX), a biotechnology company focused on metabolic and endocrine disorders, has seen a mix of analyst reactions and financial results in the second quarter of 2025. Cantor Fitzgerald reiterated its Overweight rating and $104.00 price target on the company, while Citi has boosted its price target from $31 to $38, maintaining a Neutral rating. The firm expects growing investor interest as Phase 2 data for VK2735 approaches later this year.

The company reported a net loss of $65.6 million or $0.58 per share for the second quarter, which was larger than anticipated by analysts. The reported loss exceeded both the consensus estimate of $0.44 and H.C. Wainwright’s forecast of $0.42 per share. Increased research and development expenses, totaling $60.2 million, contributed to the higher-than-expected loss. Despite the earnings miss, H.C. Wainwright has reiterated its Buy rating for Viking Therapeutics, maintaining a price target of $102.

Viking Therapeutics maintains a strong financial position with over $800 million in cash, as reported by the company. The firm's stock rose by 4.05% in aftermarket trading, indicating investor optimism about future growth prospects and ongoing developments in the obesity treatment sector.

The company has made significant progress in its clinical pipeline. The VANQUISH Phase 3 registration trials for VK2735 are underway, with two studies targeting enrollment of approximately 4,500 adults with obesity and 1,100 adults with type 2 diabetes. The Phase 2 VENTURE-Oral Dosing trial, which aims to evaluate the safety, tolerability, and efficacy of VK2735 as an oral tablet, has completed enrollment and is expected to report top-line results in the second half of 2025.

The average target price for VKTX is $89.19, implying an upside of 167.03% from the current price. Analysts remain bullish on the company's long-term potential, with price targets ranging from $33 to $125. Viking Therapeutics continues to make progress towards an IND filing for its dual amylin and calcitonin receptor agonist (DACRA) program, which is expected in the fourth quarter of 2025.

These recent developments highlight the mixed reactions from the market and analysts regarding Viking Therapeutics’ financial performance and future outlook. The company's strong financial position and ongoing clinical trials suggest that investors should closely monitor the upcoming Phase 2 data and other corporate developments.

References:
[1] https://www.investing.com/news/analyst-ratings/viking-therapeutics-stock-rating-reiterated-by-cantor-fitzgerald-at-104-93CH-4151063
[2] https://ir.vikingtherapeutics.com/2025-07-23-Viking-Therapeutics-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Corporate-Update